Experimental HIV vaccine is well-tolerated in adults

Experimental HIV vaccine is well-tolerated in adults

Researchers have found that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against the deadly virus in healthy adults.The findings by APPROACH, an early-stage clinical trial are based on "mosaic" technology that combines immune-stimulating proteins from four different HIV strains, representing different types of virus from around the globe.

The new vaccine:

  • The new vaccine regimen called as "Ad26 mosaic".
  • It was well-tolerable.
  • In addition,capable of generating anti-HIV immune responses in healthy HIV-negative adults.
  • Importantly, Ad26 mosaic is most protective in pre-clinical studies in animals.
  • Furthermore, elicited among the greatest immune responses in the study participants.
  • Anthony S. Fauci, Director at the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland.
  • He said,a safe and effective HIV vaccine would be a powerful tool to reduce new HIV infections worldwide.
  • In addition,help bring about a durable end to the HIV/AIDS pandemic.
  • By exploring multiple promising avenues of vaccine development research.
  • We expand our opportunities to achieve these goals," Fauci added.

Study says:

  • The results were presented at the ninth International AIDS Society Conference on HIV Science in Paris.
  • For the study, APPROACH involved nearly 400 volunteers in the US, Rwanda.
  • In addition,Uganda, South Africa and Thailand who were randomly assign.
  • To receive one of seven experimental vaccine regimens.

Ad26 mosaic vaccine:

  • The Ad26 mosaic vaccine delivers its four immunogens to human cells.
  • In addition,through a common cold virus that is genetically engineer to cause infection but not illness.
  • The results showed that Ad26 is safe.
  • Also,triggered a strong immune response to the different HIV strains in the volunteers.
  • In addition,the promising, early-stage results from the APPROACH study.
  • Furthermore,supports evaluation of these candidate vaccines to assess their ability to protect.
  • In addition, those at risk of acquiring HIV, the researchers said.

Share it
Share it
Share it
Top